JP2018520999A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520999A5 JP2018520999A5 JP2017559043A JP2017559043A JP2018520999A5 JP 2018520999 A5 JP2018520999 A5 JP 2018520999A5 JP 2017559043 A JP2017559043 A JP 2017559043A JP 2017559043 A JP2017559043 A JP 2017559043A JP 2018520999 A5 JP2018520999 A5 JP 2018520999A5
- Authority
- JP
- Japan
- Prior art keywords
- lys
- asp
- dval
- dala
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 206010016654 Fibrosis Diseases 0.000 claims 15
- 230000004761 fibrosis Effects 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 150000001413 amino acids Chemical group 0.000 claims 7
- 230000004054 inflammatory process Effects 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 5
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 4
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 3
- 230000002490 cerebral effect Effects 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000006154 Chronic hepatitis C Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 2
- 101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 108010034143 Inflammasomes Proteins 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 206010067125 Liver injury Diseases 0.000 claims 2
- 208000004852 Lung Injury Diseases 0.000 claims 2
- 206010072208 Oesophageal fibrosis Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 206010061481 Renal injury Diseases 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims 2
- 208000018839 Wilson disease Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 231100000753 hepatic injury Toxicity 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 2
- 230000007574 infarction Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 208000018191 liver inflammation Diseases 0.000 claims 2
- 231100000515 lung injury Toxicity 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 210000000651 myofibroblast Anatomy 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 241000024188 Andala Species 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 102000001189 Cyclic Peptides Human genes 0.000 claims 1
- 108010069514 Cyclic Peptides Proteins 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 208000032376 Lung infection Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010034665 Peritoneal fibrosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000016977 Secondary sclerosing cholangitis Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 239000003518 caustics Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108091005601 modified peptides Proteins 0.000 claims 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160173P | 2015-05-12 | 2015-05-12 | |
| US62/160,173 | 2015-05-12 | ||
| PCT/US2016/026966 WO2016182660A1 (en) | 2015-05-12 | 2016-04-11 | Peptide treatment for inflammation and fibrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520999A JP2018520999A (ja) | 2018-08-02 |
| JP2018520999A5 true JP2018520999A5 (enExample) | 2021-02-25 |
| JP7372026B2 JP7372026B2 (ja) | 2023-10-31 |
Family
ID=57248348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017559043A Active JP7372026B2 (ja) | 2015-05-12 | 2016-04-11 | 炎症および線維症のペプチド治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10434134B2 (enExample) |
| EP (1) | EP3294752B1 (enExample) |
| JP (1) | JP7372026B2 (enExample) |
| CN (3) | CN114181281A (enExample) |
| AU (1) | AU2016260190A1 (enExample) |
| CA (1) | CA2984769C (enExample) |
| WO (1) | WO2016182660A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016260190A1 (en) * | 2015-05-12 | 2017-11-23 | The Regents Of The University Of California | Peptide treatment for inflammation and fibrosis |
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| RU2019123160A (ru) * | 2016-12-29 | 2021-01-29 | Юниверсити Оф Майами | Способ модуляции активности инфламмасом и воспаления в легком |
| SG11202013176VA (en) | 2018-07-03 | 2021-01-28 | Univ Miami | Compositions and methods for treating inflammasome related diseases or conditions |
| JP7659499B2 (ja) * | 2018-10-25 | 2025-04-09 | ネクセル カンパニー，リミテッド | 線維症を治療又は予防するための組成物及び方法 |
| CN111770539B (zh) | 2019-04-02 | 2021-07-09 | 大唐移动通信设备有限公司 | 一种lmf选择方法、终端定位服务方法及装置 |
| WO2021101966A1 (en) * | 2019-11-18 | 2021-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of fibrosis with combined blockade of il-6 and immune checkpoint |
| CN114134191B (zh) * | 2020-09-04 | 2023-12-12 | 琛蓝(美国)营养制品股份有限公司 | 一种抗炎护肾的蛤蜊肽的制备方法和应用 |
| CN112960780B (zh) * | 2021-03-03 | 2023-02-03 | 龙江环保集团股份有限公司 | 一种生物膜载体的预处理方法及生物法污水处理工艺 |
| DE102022203153A1 (de) | 2022-03-31 | 2023-10-05 | Psa Automobiles Sa | Stauraumanordnung für einen Innenraum eines Fahrzeugs, Fahrzeug mit der Stauraumanordnung und Verfahren zur Benutzung einer Stauraumanordnung |
| KR102772405B1 (ko) * | 2022-06-10 | 2025-02-26 | (주)케어젠 | 근육 손실 저해 및 근육량 증진 활성을 갖는 펩타이드 및 이의 용도 |
| CN115850440B (zh) * | 2022-12-09 | 2023-07-11 | 中国人民解放军陆军军医大学 | 一种长链MyD88诱饵肽及其作为药物的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8129349B2 (en) * | 2000-10-27 | 2012-03-06 | The Regents Of The University Of California | Treatment of disease by inducing cell apoptosis |
| US7402567B2 (en) * | 2000-10-27 | 2008-07-22 | The Regents Of The University Of California | Treatment of disease by inducing cell apoptosis |
| WO2002054938A2 (en) * | 2000-10-27 | 2002-07-18 | The Regents Of The University Of California | Treatment of disease by inducing cell apoptosis |
| CN1678336A (zh) * | 2002-02-21 | 2005-10-05 | 加州大学校务委员会 | 用细胞凋亡诱导方法治疗疾病 |
| US7119071B2 (en) * | 2002-05-21 | 2006-10-10 | University Of Medicine And Dentistry Of New Jersey | Amino terminal substance P compositions and methods for using the same |
| MX2007013430A (es) * | 2005-04-29 | 2008-03-19 | Univ California | Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria. |
| CN101227918A (zh) * | 2005-04-29 | 2008-07-23 | 加州大学评议会 | 治疗以炎症反应为特征的病理的肽和肽模拟物 |
| US8865657B2 (en) * | 2005-08-19 | 2014-10-21 | New York University | Compositions and methods for inactivating or suppressing inflammatory cells |
| EP2324048A2 (en) * | 2008-07-30 | 2011-05-25 | Cosmix Therapeutics Llc | Peptide therapeutics that bind vegf and methods of use thereof |
| HK1198333A1 (zh) * | 2011-07-19 | 2015-04-02 | Thrasos Innovation, Inc. | 抗纤维化肽及其在用於治疗以纤维化为特徵的疾病和病症的方法中的用途 |
| CA2864100A1 (en) * | 2012-02-14 | 2013-08-22 | The Regents Of The University Of California | Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions |
| AU2016260190A1 (en) * | 2015-05-12 | 2017-11-23 | The Regents Of The University Of California | Peptide treatment for inflammation and fibrosis |
-
2016
- 2016-04-11 AU AU2016260190A patent/AU2016260190A1/en not_active Abandoned
- 2016-04-11 WO PCT/US2016/026966 patent/WO2016182660A1/en not_active Ceased
- 2016-04-11 JP JP2017559043A patent/JP7372026B2/ja active Active
- 2016-04-11 CN CN202111595612.6A patent/CN114181281A/zh active Pending
- 2016-04-11 CN CN201680024300.0A patent/CN107531752B/zh active Active
- 2016-04-11 US US15/570,910 patent/US10434134B2/en active Active
- 2016-04-11 EP EP16793126.0A patent/EP3294752B1/en active Active
- 2016-04-11 CA CA2984769A patent/CA2984769C/en active Active
- 2016-04-11 CN CN202210439797.XA patent/CN114621318A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520999A5 (enExample) | ||
| US9169290B2 (en) | Peptides and their use | |
| KR101965467B1 (ko) | 아드레노메둘린의 폴리에틸렌 글리콜 기반 전구약물 및 그의 용도 | |
| JP2015533833A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| ES2845612T3 (es) | Composiciones de profármaco de alta penetración de péptidos y compuestos relacionados con péptidos | |
| FI3723782T3 (fi) | Peptidejä ei-alkoholiperäisen rasvamaksataudin hoitoon ja ennaltaehkäisyyn | |
| RU2010114034A (ru) | Терапевтическое применение нейропептида ei и acth 7-38 и их комбинаций | |
| JP2010508305A5 (enExample) | ||
| IL316406A (en) | Lipid-modified relaxin B peptide chains and their medical use | |
| JP2012115277A5 (enExample) | ||
| JP2014527040A5 (enExample) | ||
| JP2015509950A5 (enExample) | ||
| JP2019513752A5 (enExample) | ||
| MX2022003057A (es) | Nuevos peptidos. | |
| HRP20221046T1 (hr) | Beta-ukosni peptidomimetici kao selektivni inhibitori elastaze | |
| JP2013529916A5 (enExample) | ||
| JP2017522350A5 (enExample) | ||
| JP2010083896A5 (enExample) | ||
| JP2803477B2 (ja) | ヘキサペプチド | |
| CR20250156A (es) | DERIVADOS DE BENZIMIDAZOL CÍCLICO COMO INHIBIDORES DE cGAS | |
| JP2020515283A5 (enExample) | ||
| CN105440110A (zh) | 一种抗炎环肽Cyclosquamosin D的化学合成方法 | |
| IL299778A (en) | Therapeutic use of glucagon derivative or conjugate thereof for liver disease | |
| JP2013518061A5 (enExample) |